Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DanNORMS
2020-002981-15Phase 3Active
- Sponsor
- Danish Multiple Sclerosis Center, Rigshospitalet
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) comparing ocrelizumab arm with rituximab arm (2 arms). Primary endpoint: Percentage of patients with no new or enlarging T2 white matter lesions. Started Jul 2020; status: active.
02
Drugs
ocrelizumabrituximab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2020-002981-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002981-15.